The struggle over how best to address COVID-19 has become increasingly partisan. The public fight over the value of hydroxychloroquine as a helpful treatment should be (but isn’t) driven by the evidence, according to Cato’s Jeff Singer.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.